Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 5/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | NPSR1 | Q6W5P4 | 3/20 | 0.39 |
| ▸ | RECQL | P46063 | 1/20 | 0.39 |
| ▸ | GPR119 | Q8TDV5 | 2/20 | 0.37 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.36 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
| ▸ | ABL1 | P00519 | 3/20 | 0.36 |
| ▸ | HPGD | P15428 | 7/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | RNASEL | Q05823 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL653891 | 0.92 | MAPT (0.41) | MAPTLMNANPSR1RECQLGPR119 | |
| SCHEMBL653892 | 0.92 | MAPT (0.41) | MAPTLMNANPSR1RECQLGPR119 | |
| SCHEMBL10176480 | 0.90 | MAPT (0.41) | MAPTLMNANPSR1RECQLGPR119 | |
| SCHEMBL698911 | 0.89 | MAPT (0.38) | MAPTLMNANPSR1RECQLGPR119 | |
| SCHEMBL10176528 | 0.88 | MAPT (0.42) | MAPTLMNANPSR1RECQLMAPK1 | |
| SCHEMBL10176507 | 0.88 | MAPT (0.40) | MAPTLMNANPSR1RECQLGPR119 | |
| SCHEMBL10176547 | 0.87 | MAPT (0.47) | MAPTLMNANPSR1RECQLMAPK1 | |
| SCHEMBL10176532 | 0.86 | PTPN7 (0.44) | MAPTLMNANPSR1RECQLMAPK1 | |
| SCHEMBL653447 | 0.85 | MAPT (0.39) | MAPTLMNANPSR1RECQLGPR119 | |
| SCHEMBL653370 | 0.84 | MAPT (0.40) | MAPTLMNANPSR1RECQLMAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8119812-B2 | Thiazolidinone derivative | SBI BIOTECH CO., LTD. (JP) | 2012-02-21 | — | — | US | disclosed |
| US-20110190299-A1 | THIAZOLIDINONE DERIVATIVE | SBI BIOTECH CO., LTD. (JP) | 2011-08-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110190299-A1 | THIAZOLIDINONE DERIVATIVE | CDC7, CDK17, CDCA2 | MAPT 3657/4885LMNA 3772/4885NPSR1 4464/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.